A phase I dose-escalation clinical trial to evaluate the safety and immunogenicity of a multiclade, multivalent recombinant adenoviral vector HIV vaccine, VRC-HIVADV014-00-VP, in healthy, HIV-1 uninfected adult participants who have low titers of pre-existing Ad5 neutralizing antibodies.

Trial Profile

A phase I dose-escalation clinical trial to evaluate the safety and immunogenicity of a multiclade, multivalent recombinant adenoviral vector HIV vaccine, VRC-HIVADV014-00-VP, in healthy, HIV-1 uninfected adult participants who have low titers of pre-existing Ad5 neutralizing antibodies.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs VRC-HIVADV014-00-VP (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 03 May 2012 Actual end date changed from Sep 2009 to Oct 2006 sa reported by ClinicalTrials.gov.
    • 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top